INS and Insulin resistance: There is clear evidence for the clinical benefits of metformin treatment in individuals with T2D and insulin resistance as it notably improves insulin sensitivity and may lower the risk of CVD which is potentially mediated through improved lipid profiles (27), despite having little effect on IHTG content.